Medical and Economical Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases

Trial Profile

Medical and Economical Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Sulfur hexafluoride (Primary)
  • Indications Cancer metastases; Colorectal cancer
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2016 Results of ancillary study (n=130) assessing bevacizumab pharmacokinetics using a two-compartment pharmacokinetic population model, published in the Clinical Pharmacokinetics Journal.
    • 16 Jun 2016 Results of two-compartment pharmacokinetic population model (n=130) published in the Clinical Pharmacokinetics.
    • 19 Feb 2009 Planned end date changed from 1 Jun 2008 to 1 Mar 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top